Earlier studies of quinine concentrations after intramuscular injection were encouraging,"2528 although none of this work excluded the possibility of transient but toxic peak concentrations. Our results show that a loading dose results in therapeutic plasma concentrations within four hours of injection and that absorption is reliable in patients with moderately severe malaria without the risk of high peaks seen after intramuscular chloroquine (see accompanying paper, p 11 
0, 12, and 24 hours. Both regimens were completed with oral chloroquine phosphate, 5 mg base/kg, at 36 and 48 hours. Mean peak chloroquine concentrations in the first 12 hours, which were 0-5 (range 0-3-0-6) mg/l (1.4 (0.9-1-7) mmolil) with the intramuscular regimen and 0*3 (0.2-0.4) mg/l (1.0 (0-7-1-3) mmol/l) with the subcutaneous regimen (p<005), were reached in median times of 90 (65-90) minutes and 30 (30-60) minutes respectively (p<OOS) after the start of treatment. The mean area under the plasma concentration curve for the first 12 hours was 1-4 (0-9-2.1) mg/l.h (4.5 (2.8-6.4) mmol/l.h) after intramuscular administration and 1-8 (0.8-2.3) mg/l.h (5.7 (2.7-7.2) mmol/l.h) after subcutaneous administration (p>0 1). Mean maximum plasma concentrations were higher after intramuscular administration (0-6 (0.4-0.8) mg/I (1-7 (1-3-2-5) mmol/l)) than after subcutaneous administration (0.4 (0.4-0.5) mg/l (1-3 (1-3-1.5) mmol/l)) (p<0-05), but both regimens produced satisfactory plasma profiles. Chloroquine resistance was found in the only case of Plasmodium falciparum malaria.
Chloroquine is absorbed rapidly after divided dose intramuscular injection and single dose subcutaneous injection and does not cause hypotension or neurotoxicity in adults. Similar regimens should be evaluated in children before the parenteral use of this drug is abandoned. Introduction A World Health Organisation (WHO) scientific group has recommended that the use of parenteral chloroquine should be abandoned world wide.' This arose from fears that patients with malaria who attended clinics after taking chloroquine at home would be at risk of serious toxicity if they were then given a chloroquine injection. Cases of sudden death after intramuscular administration of chloroquine were cited in support of this decision.24 Abandoning the use of such a widely used and lifesaving drug is a serious matter. The WHO group was influenced by the knowledge that chloroquine was often given by unsupervised paramedical staff who failed to adjust the dosage to the patient's weight, but problems of pretreatment and poor use of injectable drugs apply to all antimalarial drugs, not just chloroquine.5 Preliminary data suggested that chloroquine given intramuscularly was no less effective and no more toxic than quinine given parenterally.5 Chloroquine has been well tried and excellently tolerated in pregnancy and unlike quinine does not cause hypoglycaemia.89 A serious problem has been the complete lack of information about the pharmacokinetics and toxicity of the drug after parenteral administration.
It is now clear from studies on volunteers that cardiovascular toxicity is likely to occur only when chloroquine enters the circulation very quickly-for example, after intravenous injection.'°" Rapid absorption after intramuscular injection, a phenomenon observed in animals,'2 is suspected to have been responsible for the collapse and death of African children who were prone to hypotension because of dehydration and generalised vasodilatation. 4 This type of collapse, however, though often discussed, is virtually undocumented. '3 We report here the plasma concentrations achieved with, and the toxicity of, parenteral regimens in adults with malaria-namely, divided dose intramuscular injections and single dose subcutaneous injections.
Patients and methods
At BRITISH MEDICAL JOURNAL VOLUME 293 5 JULY 1986 cutaneously at the lateral aspect of the thigh of alternate legs on admission and then 12 and 24 hours later. In both groups of patients the course was completed by giving oral chloroquine phosphate 5 mg base/kg at 36 and 48 hours. At 15 minute intervals for one hour after the first dose, and then every 30 minutes, patients were asked about pain at the site of injection and other side effects. Injection sites were examined before every injection and then daily until the patients were discharged. Blood samples were taken, through an indwelling intravenous Teflon catheter kept patent with heparinised saline, before treatment; at five, 15, 30, 60, and 90 minutes and two, three, and six hours after the first dose; before and one and two hours after the doses at 12 and 24 hours; and before the last dose at 48 hours. Additional samples were taken at 65 and 75 minutes in patients given intramuscular chloroquine. Blood, dispensed from plastic syringes into plastic heparinised tubes, was centrifuged at 360 g for 15 minutes. Plasma, free of the buffy coat, was transferred in plastic pipettes to plastic phials and stored at -20'C for one to two weeks before being transported on dry ice to Liverpool, where it was stored at -70'C until assayed by high performance liquid chromatography.'4 All glassware was treated with dichlorodimethylsilane (5% vol/vol in toluene) to minimise drug absorption. Plasma chloroquine concentrations were analysed with a Hewlett-Packard HP-975 programmable calculator. Statistical comparisons were performed with the Mann-Whitney U test.
Results
Fourteen patients with Plasmodium vivax malaria and one patient with P falciparum malaria, all of whom had a history of fever and rigors, were studied. All but one were feverish (temperature >3750C) at the time of the first chloroquine injection. No patient had chloroquine detectable in pretreatment plasma analysed subsequently in Liverpool. The two groups receiving intramuscular and subcutaneous chloroquine were comparable (p>O 1) for age, ratio of men to women, weight, parasitaemia, and total dose of chloroquine given (table) .
Intramuscular chloroquine-All patients complained of pain at the site of injection, but none thought it severe; it lasted from 15 minutes to two hours. They did not complain of discomfort on moving the muscle once the pain had subsided, and none had any sign of induration or abscess formation. There was a non-significant fall (p>005) in blood pressure 30 and 90 minutes after the first injection ( Cowpanson of regimenPlasma chloroquine concentrations were not significatly different between the two regimens at five, 15, 30, and 60 minutes. The time taken to reach maxmum concentration in the 12 hours after the start of treatment was significantly shorter for the subcutaneous regimen (p<005), but the overal peak concentraton was significantly higr after the intramusula regimen (p<005). 
Dscussion
For decades intramuscular injection ofchloroquine has boen used throughout the tropics to treat malaria. By this method rural health workers have been able to treat patients who were vomiting or comatose, and the practice was rarely questioned, despite some reports of sudden death in children. In retrospect, it is surprising that the chemotherapy of a life threatening infection should have relied on a drug whose pharmacokinetics were so poorly understood. Until recently there had been no attempt to define the pharmacokinetics and toxicity ofchloroquine in man, yet there were sufficient data from animal experiments and patients who had taken overdoses to suggest that cardiovascular poisoning was a serious risk. '215 When the WHO became aware of a high incidence of self medication with chloroquine"6 it decided to recommend that parenteral use of this drug should be abandoned because it feared that toxic concentrations could result if intramuscular injections were given.' After this decision there was much uncertainty about parenteral chemotherapy for malaria; chloroquine has had a.generally good record of safety for nearly 40 years and the only alternative drug, quinine, is also potentially toxic. The critical data needed to make an informed decision about chloroquine were the kinetics of absorption and disposition. This deficiency has been partly corrected by recent studies in volunteers and patients with malaria. After intravenous injection transient but very high plasma chloroquine concentrations occur and all subjects report side effects such as dizziness and blurred vision."" I Hypotension and prolongation of the electrocardiographic QRS interval were detected in one study, in which cardiovascular effects were specifically sought." Absorption in aniimals after intramuscular injection was rapid,'2 and the present study shows that this is also true in man, whether the drug is injected into muscle or subcutaneous tissue. Peak chloroquine concentrations were significandy higher and were reached sooner during the intramuscular regimen, but relative bioavailability as judged by the area under the plasma concentration curve was similar. Peak concentrations were lower than those detected in volunteers given intravenous injections of similar doses,10 and the patients with malaria did not experience a change in blood pressure or neurotoxic effects.
Studies in areas where P fakiparum remained fully sensitive to chloroquine have shown no advantage for quinine, which is more expensive.67 Both drugs have potential cardiovascular toxicity, '5" particularly when given in overdose or by rapid intravenous injection."' Quinine has the additional risks of refractory hyperinsulinaemic hypoglycaemia,'' especially in pregnancy,' an association with blackwater fever,m and the potential for damage to tissue, even when injections are sterile.2 Chloroquine has an excellent safety record in pregnancy,2 and cerebral malaria in children has responded well to parenteral chloroquine. 23 Chloroquine was rapidly absorbed after subcutaneous injection in these Sri Lankan adults and in Zambians (N J White et al, unpublished findings), but in severe malaria with shock cutaneous perfusion may be sufficiendy poor to dangerously impede systemic absorption ofthe drug. Under circumstances where therapeutic blood concentrations must be reached as quickly and reliably as possible, such as in cerebnl malaria, slow intravenous (or even continuous) infusion is the best way to give chloroquine parenterally. 24 As a compromise where intravenous equipment is not available divided dose intramuscular injections, correctly adjusted for weight, allow therapeutic chloroquine concentrations to be reached quickly and reduce the risk of transient but potentially dangerous peaks that could occur if 5 mg base/kg was injected as a single dose. In shocked patients, however, absorption of chloroquine from muscle may be inadequate so this route should not be relied on unless it is impossible to set up an intravenous infusion.
Studies of intravenous chloroquine injection have suggested that dangerous concentrations occur when the drug enters the circulation more rapidly than it can be dispersed." This could happen if absorption after intramuscular injection was particularly rapid, and this possibility must be investigated in children. Recent treatment with chloroquine could increase the risk of high concentrations,"6 but the rate ofentry of the drug into the circulation, rather than the dose, seems to be the most important determinant of acute toxicity."
Debate over the relative merits of quinine and chloroquine will continue while P falciparwn remains sensitive to chloroquine in some parts of the world. The rapid spread ofchloroquine resistance westwards in Africa and Asia (shown by the patient with falciparum malaria described above and other recent reports) may ultimately make this discussion redundant. For the time being, however, quinine is not an ideal substitute for chloroquine world wide. Radical cure with quinine alone is difficult to achieve, as the drug can cause serious toxicity, and it has never been shown to be superior to chloroquine for infections sensitive to chloroquine. Acute chloroquine toxicity seems to be predictable and can be circumvented by controlled administration. There are too few alternative drugs for us to abandon chloroquine for the treatment of severe malaria; the recommendation to do so should be revised.
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